We are live on ! Find out more
EW icon

Edwards Lifesciences

556 hedge funds and large institutions have $11.7B invested in Edwards Lifesciences in 2014 Q4 according to their latest regulatory filings, with 97 funds opening new positions, 193 increasing their positions, 182 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 97 | Existing positions closed: 31

50% more funds holding in top 10

Funds holding in top 10: 1015 (+5)

12% more funds holding

Funds holding: 496556 (+60)

6% more repeat investments, than reductions

Existing positions increased: 193 | Existing positions reduced: 182

5% less capital invested

Capital invested by funds: $12.4B → $11.7B (-$651M)

7.78% less ownership

Funds ownership: 523.44%515.66% (-7.8%)

15% less call options, than puts

Call options by funds: $44.3M | Put options by funds: $52.1M

Holders
556
Holders Change
+60
Holders Change %
+12.1%
% of All Funds
14.83%
Holding in Top 10
15
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+50%
% of All Funds
0.4%
New
97
Increased
193
Reduced
182
Closed
31
Calls
$44.3M
Puts
$52.1M
Net Calls
-$7.8M
Net Calls Change
-$17.2M
Name Holding Trade Value Shares
Change
Change in
Stake
WTB
551
Washington Trust Bank
Washington
$5K
GGPS
552
Gary Goldberg Planning Services
New York
$4K +$3.86K +192 New
CAW
553
Cornerstone Advisors (Washington)
Washington
$3K
VIA
554
Vantage Investment Advisors
Pennsylvania
$3K
BRWA
555
B. Riley Wealth Advisors
Florida
$6 +$6.03K +300 New
NTC
556
North Tide Capital
Massachusetts
-$76.6M -4,500,000 Closed
FC
557
Fairpointe Capital
Illinois
-$71.4M -4,193,820 Closed
Mackenzie Financial
558
Mackenzie Financial
Ontario, Canada
-$63.5M -3,731,400 Closed
Point72 Asset Management
559
Point72 Asset Management
Connecticut
-$21.1M -1,237,800 Closed
EA
560
Euclid Advisors
Connecticut
-$5.57M -326,880 Closed
GACM
561
Green Arrow Capital Management
New York
-$4.09M -240,000 Closed
DCC
562
Dow Chemical Company
Michigan
-$3.17M -186,000 Closed
Carson Wealth (CWM LLC)
563
Carson Wealth (CWM LLC)
Nebraska
-$2.68M -157,584 Closed
SFU
564
Stonehage Fleming (UK)
United Kingdom
-$2.66M -156,348 Closed
GTC
565
Ghost Tree Capital
New York
-$2.55M -150,000 Closed
Los Angeles Capital Management
566
Los Angeles Capital Management
California
-$1.22M -71,820 Closed
EMG
567
Ellington Management Group
Connecticut
-$960K -56,400 Closed
AAM
568
Aston Asset Management
Illinois
-$905K -53,142 Closed
IGIM
569
I.G. Investment Management
Manitoba, Canada
-$889K -52,200 Closed
Capital Fund Management (CFM)
570
Capital Fund Management (CFM)
France
-$755K -37,584 Closed
Jane Street
571
Jane Street
New York
-$500K -29,388 Closed
CG
572
Clinton Group
New York
-$460K -27,030 Closed
GLA
573
Great Lakes Advisors
Illinois
-$441K -25,932 Closed
TRCT
574
Tower Research Capital (TRC)
New York
-$432K -25,356 Closed
LBG
575
Lloyds Banking Group
United Kingdom
-$414K -24,336 Closed

EW Hedge Fund Activity: Q4 2014 in Review

556 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q4 2014, worth a combined $11.7B — down 5.3% from $12.4B a quarter earlier.

Buyers outnumbered sellers: 97 funds opened new EW positions and 31 closed out — a net gain of 66 holders — while 193 added to existing stakes and 182 trimmed.

The largest buyer was AQR Capital Management, adding an estimated $85M. The largest seller was Capital Research Global Investors, cutting an estimated $232M.

  • 556 institutional investors held Edwards Lifesciences (EW) as of Q4 2014, up from 496 in Q3 2014.
  • Funds reported $11.7B of Edwards Lifesciences stock for Q4 2014, down 5.3% quarter-over-quarter.
  • 97 funds opened new Edwards Lifesciences positions in Q4 2014 and 31 closed out, a net change of +66 holders.
  • The largest Edwards Lifesciences buyer in Q4 2014 was AQR Capital Management, an estimated $85M added.
  • The largest Edwards Lifesciences seller in Q4 2014 was Capital Research Global Investors, an estimated $232M sold.

Based on aggregated 13F filings for Q4 2014.